In the endometrium, hormonal effects on epithelial cells are often elicited through stromal hormone receptors via unknown paracrine mechanisms. Several lines of evidence support the hypothesis that Wnts participate in stromal-epithelial cell communication. Wnt7a is expressed in the luminal epithelium, whereas the extracellular modulator of Wnt signaling, secreted frizzled-related protein 4 (SFRP4), is localized to the stroma. Studies have reported that SFRP4 expression is significantly decreased in endometrial carcinoma and that both SFRP4 and Wnt7a genes are differentially regulated in response to estrogenic stimuli. Aberrant Wnt7a signaling irrevocably causes organ defects and infertility and contributes to the onset of disease. However, specific frizzled receptors (Fzd) that bind Wnt7a and the particular signal transduction pathway each Wnt7a-Fzd pair activates have not been identified. Additionally, the function of SFRP4 in the endometrium has not been addressed. We show here that Wnt7a coimmunoprecipitates with Fzd5, Fzd10, and SFRP4 in Ishikawa cells. Wnt7a binding to Fzd5 was shown to activate B-catenin/canonical Wnt signaling and increase cellular proliferation. Conversely, Wnt7a signaling mediated by Fzd10 induced a noncanonical c-Jun NH 2 -terminal kinase -responsive pathway. SFRP4 suppresses activation of Wnt7a signaling in both an autocrine and paracrine manner. Stable overexpression of SFRP4 and treatment with recombinant SFRP4 protein inhibited endometrial cancer cell growth in vitro. These findings support a mechanism by which the nature of the Wnt7a signal in the endometrium is dependent on the Fzd repertoire of the cell and can be regulated by SFRP4.
Introduction
The uterine endometrium is a complex tissue that responds to numerous hormones and undergoes dynamic reorganization during the menstrual cycle in preparation for implantation (1) . The development, growth, and functional differentiation of the endometrium are dependent on a dynamic collaboration between its constituent stromal and epithelial cells (2) . Hormonal effects on epithelial cells are often elicited through stromal hormone receptors via paracrine mechanisms (3, 4) . Recombination experiments using estrogen receptor a knockout and wild-type tissues showed that it is the stromal cell estrogen receptors that are responsible for mediating epithelial proliferation induced by estrogen (5) . Progesterone acting on the stromal compartment opposes estrogen-induced epithelial proliferation and regulates paracrine mediators that influence epithelial gene expression. However, the complete nature of the paracrine signaling and the molecular basis of how stromal and epithelial cells communicate to one another remain largely unknown. Wnt7a is expressed in the endometrium and levels have been shown to fluctuate in response to circulating steroid hormones during the menstrual cycle and pregnancy (6) . Wnt7a is required for proper differentiation and gland formation during uterine development. Following postnatal growth, Wnt7a expression becomes restricted primarily to the luminal epithelium and is responsible for maintaining expression of other Wnts in the stroma (6) (7) (8) (9) . Given that Wnts undergo hormone regulation and different Wnts are generally localized to different cell types in the endometrium suggests that Wnt signaling may play a key role in the action of steroid hormones and in mediating intercellular communication in the endometrium.
Members of the Wnt signaling family are highly conserved, secreted glycoproteins that are vital to mammalian development and many aspects of adult tissue homeostasis. Wnts regulate important cellular processes, such as proliferation, differentiation, and cell fate specification (10) . The binding of a Wnt ligand to its corresponding seven-transmembrane frizzled receptor (Fzd) leads to the activation of at least one of the three possible signaling pathways: (a) the h-catenin/canonical pathway, (b) the planar cell polarity/c-Jun NH 2 -terminal kinase (JNK) pathway, and (c) the Ca 2+ -mediated pathway (10, 11) . The complexity of mammalian Wnt signaling is exemplified by the fact that there are currently 19 known mammalian Wnts and 10 Fzds (10, 12) . Despite the numerous studies that have been done to date, it has yet to be completely elucidated which particular Wnts bind to which Fzds and what signal transduction pathway each Wnt-Fzd pair activates.
In the traditional canonical pathway, Wnts released from or presented on the surface of signaling cells act on target cells by binding with high affinity to Fzd, which forms a complex with Lrp5/6 coreceptor (13) . This interaction results in the cytoplasmic accumulation of stabilized h-catenin, which translocates to the nucleus where it can associate with members of the lymphoid enhancer factor/T-cell factor class of transcription factors and induce transcription of genes, including c-myc and cyclin D (14) (15) (16) (17) . In the absence of a Wnt signal, cytoplasmic h-catenin levels are otherwise kept low through a proteasomemediated degradation (18) . It has been established that the b-catenin gene is mutated at a frequency rate of 30% in type I endometrial carcinoma (19, 20) . Mutated b-catenin can resist degradation and subsequently act as an oncogene affecting cell adhesion and constitutively activating Wnt target gene expression. In the noncanonical planar cell polarity/JNK pathway, Wnt interaction with Fzd facilitates the recruitment of small GTPases RhoA/Rac/cdc42 and triggers the consequent phosphorylation and activation of c-Jun (12, 21) . The Ca 2+ -mediated pathway involves heterotrimeric G proteins and subsequent activation of protein kinase C, Ca 2+ -calmodulindependent kinase II, nuclear factor associated with T cells, and other downstream effectors (22) (23) (24) .
There are a host of diverse proteins that function as extracellular modulators of Wnt signaling, including members of the secreted frizzled-related protein (SFRP) family (25) . SFRPs share sequence homology with the cysteine-rich domain (CRD) of Fzd and are thought to antagonize Wnt action by competing with Fzd for the binding of Wnts and preventing Wnt-Fzd interaction (25) . The identification of specific Wnt-SFRP associations is another important, but ill defined, area of Wnt research that requires a further in-depth exploration.
SFRP4 is restricted to the endometrial stroma and its expression has been shown to peak during the proliferative (or estrogen dominated) phase of the menstrual cycle. Quantitative reverse transcription-PCR (RT-PCR) studies done in our laboratory found that in postmenopausal women treated with estrogen for 3 months SFRP4 expression in the endometrium increased 9-fold. 1 SFRP4 expression levels are significantly decreased in endometrial cancer (26) (27) (28) (29) . Downregulation of SFRP4 and associated promoter hypermethylation has been reported in several other cancers, including mesothelioma, chronic lymphocytic leukemia, and esophageal adenocarcinoma (30) (31) (32) . Although it is recognized that SFRP4 plays a role in adult uterine function and is a potential biomarker for certain cancers, its Wnt binding partners and overall mechanism of action remain unclear.
In the present study, we report that Wnt7a activates hcatenin/canonical signaling and functions to induce endometrial cell proliferation in the presence of Fzd5 but not Fzd10. Wnt7a signaling mediated by Fz10 was shown to stimulate the noncanonical JNK-responsive pathway. Activation of both Wnt7a-induced pathways was inhibited through the addition of SFRP4. We also show that SFRP4 inhibition of endometrial cancer cell growth signifies its potential role as a tumor suppressor. These observations indicate that the Fzd receptor milieu within the cell dictates which signal Wnt7a elicits within the endometrium and that SFRP4 is a key regulator of Wnt7a action.
Results

Identification of Wnt Components in Ishikawa Cells
Using microarray analysis, we assessed the relative expression levels for each Wnt, Fzd, and Wnt signaling antagonist from grouped sample data of the well-differentiated human endometrial adenocarcinoma Ishikawa cell line. Results listed in Table 1 indicate gene symbol, detection signal, and P value scores where significance level is P V 0.01 based on a t test following background subtraction and rank invariant normalization. Our survey revealed that Wnt3, Wnt3a, and Wnt7a were expressed at the highest levels. It was anticipated that Wnt7a would be expressed because it is of epithelial cell Localization of Wnt7a, Fzd5, Fzd10, and SFRP4 Our previous quantitative RT-PCR screening studies have revealed mRNA expression of Fzd5 and Fzd10 in both human and rat endometrium. 1 We investigated the cell type -specific expression of Wnt7a, Fzd5, Fzd10, and SFRP4 in tissue sections taken from rat uteri. In situ hybridization using antisense probes revealed specific distributions of the Wnt7a transcripts in the luminal epithelium and SFRP4 in the stroma (Fig. 1 ). Fzd5 expression was apparent in both stromal and glandular epithelial cell types, with minimal expression in the luminal epithelium. Fzd10 localization was restricted mainly to the stroma (Fig. 1 ) and was not detectable in the luminal epithelium. Control sections treated with sense probes specific to each individual Wnt component showed no detectable signals. These findings indicate a complex pattern of tissue expression within the endometrium.
Interaction of Wnt7a with Fzd5 and Fzd10
To address the question of whether Wnt7a can associate physically with the extracellular Wnt binding region of Fzd5 and/or Fzd10, we did a series of coimmunoprecipitation experiments. Cells were transfected with empty vector (EV) and Wnt7a or cotransfected with Wnt7a and Fzd5 or Wnt7a and Fzd10 and then lysates were coimmunoprecipitated with an antibody directed against Wnt7a. Western blot analysis using antibody against the V5 tag confirmed that both Fzd5 and Fzd10 successfully pulled down with Wnt7a ( Fig. 2A) . As a negative control, lysate from cells overexpressing Fzd5 was immunoprecipitated with anti-Wnt7a to verify that Fzd5 did not bind nonspecifically ( Fig. 2A, middle) . We also did a reverse experiment to show that Wnt7a ligand coimmunoprecipitates with receptor by using a Fzd5 antibody ( Fig. 2A, right) . The experiment was not repeated for Fzd10 due to the unavailability of a quality Fzd10 antibody. These data corroborate that Wnt7a interacts with both Fzd5 and Fzd10.
Wnt7a Activation of the b-Catenin/Canonical Pathway Occurs via Fzd5
To determine if the Wnt7a interaction with Fzd5 and Fzd10 could induce h-catenin/canonical Wnt signaling, we used the luciferase reporter construct TopFlash. The TopFlash construct contains T-cell factor -binding sites, which are directly activated by the T-cell factor/h-catenin complex. Alternatively, the FopFlash construct, which contains mutated T-cell factorbinding sites, served as a negative control. Ishikawa cells were transiently transfected with TopFlash or FopFlash and Wnt7a, Fzd receptor, or Wnt7a plus Fzd receptor. A Renilla-TK luciferase reporter was cotransfected for assay normalization. Cotransfection of Wnt7a and Fzd5 was shown to significantly induce TopFlash activity 5.6-fold (P V 0.05; Fig. 2B ). Transfection of Fzd5 alone yielded a slight increase in TopFlash but did not reach significance. Fzd10, Wnt7a, and Wnt7a-Fzd10 failed to induce any reporter activity. Because Ishikawa cells contain endogenous Wnts, including Wnt7a, it is likely that the binding of endogenous Wnts to Fzd5 accounts for the increase in TopFlash activity when Fzd5 is transfected alone. Altogether, it is apparent that Wnt7a activation of h-catenin/ canonical Wnt signaling is mediated through Fzd5 and not Fzd10 in Ishikawa cells.
As a means to test whether Wnt7a could activate h-catenin/ canonical signaling in a concentration-dependent manner, TopFlash experiments were done using Ishikawa cells transfected with Fzd5 and increasing amounts of the Wnt7a FIGURE 1. Localization of Wnt components in the endometrium. In situ hybridization was carried out on tissue sections of the rat uterus using sense and antisense digoxigenin-labeled RNA probes. Wnt7a is localized to the luminal epithelium of the endometrium. Fzd5 expression is apparent in both the stroma and glandular epithelium, whereas Fzd10 and SFRP4 are confined solely to the stroma. g, glands; le, luminal epithelium; s, stroma. Arrows designate areas of expression.
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Mol Cancer Res 2008;6(6). June 2008 expression construct. Western blot analysis verified that the level of Wnt7a protein expression increased with greater amounts of transfected Wnt7a construct, whereas Fzd5 receptor levels remained constant (Fig. 2C) . The appearance of a slight increase in Fzd5 expression with cotransfection of 2 and 4 Ag of Wnt7a can be attributed to overexposure. A longer exposure time was necessary to visualize the smaller amounts of Wnt7a. Luciferase measurements confirmed that 2 Ag Wnt7a cotransfected with 1 Ag Fzd5 was sufficient to produce significant activation of h-catenin when compared with 1 Ag Fzd5 baseline (P V 0.05; Fig. 2D ). Transfection of 1, 2, and 4 Ag increased h-catenin signaling 1.7-, 2.8-, and 4.3-fold, respectively. This illustrates that, in Ishikawa cells, h-catenin/canonical signaling can be induced by Wnt7a in a dose-responsive manner in the presence of Fzd5.
SFRP4 Inhibition of b-Catenin/Canonical Signaling
To detect potential inhibition of Wnt7a signaling, SFRP4 was transfected alone or cotransfected with Fzd5 and Wnt7a.
Cotransfection of SFRP4 with Wnt7a and Fzd5 significantly diminished TopFlash activity to near baseline levels (Fig. 3A) . To confirm an interaction between Wnt7a and SFRP4, coimmunoprecipitation experiments were done (Fig. 3B ). Cells were transfected with Wnt7a or SFRP4 plus or minus Wnt7a. Because SFRPs are secreted proteins, transfected cells were treated with the hydrophilic cross-linking reagent 3,3 ¶-dithiobis(sulfosuccinimidylpropionate) (DTSSP) to capture proteinprotein interactions occurring at the cell surface. Lysates were immunoprecipitated with either anti-Wnt7a or anti-SFRP4 and Western blotted with anti-V5. Our results suggest that inhibition of Wnt7a-mediated h-catenin/canonical signaling in transfected cells occurs through a direct interaction of Wnt7a with SFRP4.
To assess the levels of accumulated h-catenin protein, cytosolic extracts were prepared from Ishikawa cells transfected with EV, Wnt7a and Fzd5, or Wnt7a and Fzd5 plus SFRP4. A cellular fractionation method was necessary to ensure that only cytosolic h-catenin protein stabilized due to Wnt signaling would be detected and not the relatively stable pool of h-catenin that is membrane associated with cadherins. A 9.8-fold increase in cytosolic h-catenin accumulation was observed in the presence of Wnt7a and Fzd5 compared with control transfectants (Fig. 3C) . A 2-fold reduction in the h-catenin levels was observed as a consequence of SFRP4. These data indicate that the Wnt7a signal is initiated in the presence of Fzd5 and can be at least partially ablated by SFRP4.
SFRP4 Suppresses b-Catenin/Canonical Signaling through a Paracrine Mechanism
To determine whether SFRP4 could inhibit Wnt7a-induced canonical signaling in a paracrine fashion, a series of coculture experiments were done. One cell population, referred to as effector cells, was either transfected with EV or manipulated to overexpress SFRP4. The target cell population was transfected with EV or Fzd5 receptor plus Wnt7a, Renilla-TK, and the TopFlash reporter gene. When these two cell populations were mixed, SFRP4 effector cells significantly inhibited h-catenin/canonical signaling in both EV and Wnt7a/Fzd5 target cells by 2-and 2.8-fold, respectively (Fig. 3D) . The coculture experiment was also done using a constitutively active form of h-catenin as a negative control for SFRP4 inhibition and to show that SFRP4 was not toxic to the target cell population. As shown in Ishikawa cells were transfected to express the proteins as indicated and then hypotonically lysed for Western blot analysis of cytosolic fractions. Blots were probed with anti-V5 to confirm expression of transfected proteins, anti-h-catenin, and anti-h-actin for loading control. Quantification of h-catenin was normalized to levels of h-actin and designated as fold difference relative to control transfection. D. SFRP4 inhibits Wnt7a-Fzd5 -stimulated TopFlash activity in a paracrine assay. Target Ishikawa cells, cotransfected with EV or Fzd5 plus Wnt7a, TopFlash reporter, and Renilla-TK, were cocultured with EV or SFRP4 effector cells 24 h after transfection. Cells were assayed for luciferase activity 24 h after effector cell seeding. Inset, coculture experiment done using a constitutively active h-catenin expression construct shows a negative control for SFRP4 inhibition of canonical signaling. Results are representative of at least three separate experiments (two for h-catenin control) done in duplicate. Columns, mean; bars, SE. **, P V 0.01, Student's t test; #, P V 0.001, Student's t test, compared with EV/EV coculture.
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Mol Cancer Res 2008;6(6). June 2008 Fig. 3D (inset), SFRP4 coculture had no significant effect on h-catenin signaling. This is due to the fact that the constitutive h-catenin activity occurs downstream of SFRP4 inhibition. These data indicate that SFRP4 associates with Wnt7a in a paracrine mechanism to suppress h-catenin/canonical signaling mediated by Fzd5 in endometrial cells. (Fig. 4C ). An equivalent amount of total c-Jun was observed in each sample, indicating no change in c-Jun protein expression. These data indicate that Wnt7a is capable of activating planar cell polarity/JNK-dependent noncanonical signaling via Fzd10 and that the signal is inhibited by SFRP4.
Wnt7a Induction of JNK/Noncanonical Signaling via
Fzd10 and Repression by SFRP4 Wnt ligands can activate either canonical or noncanonical pathways, often in a cell-or tissue-dependent manner. Because Wnt7a did not activate h-catenin/canonical signaling via Fzd10 in Ishikawa cells, we wanted to test whether Wnt7a could activate the noncanonical JNK pathway. To determine whether Wnt7a activated the JNK pathway through Fzd10, we used a transcriptional reporter system to
SFRP4 Protein Directly Binds Purified Wnt7a to Inhibit Activation of b-Catenin/Canonical Signaling
Previous reports have shown that SFRPs not only bind to Wnts as a means to modulate Wnt signaling but can also bind Fzd. Given this knowledge, we tested whether SFRP4 was directly binding to Wnt7a or Fzd5 to inhibit downstream signaling. Purified Wnt7a and/or SFRP4 were incubated with protein A/G agarose and a purified fusion protein consisting of the CRD of Fzd5 and the Fc portion of human IgG or Fc IgG as a negative control. Western blot analysis confirmed that Wnt7a bound to the CRD of Fzd5 as expected, whereas SFRP4 did not (Fig. 5A ). Direct association between purified SFRP4 and Wnt7a was shown by immunoprecipitation with anti-Wnt7a. These findings verify that SFRP4 directly binds Wnt7a and not the CRD of Fzd5 to inhibit canonical signaling.
We next tested whether our purified Wnt7a and SFRP4 proteins were biologically active and capable of transducing and inhibiting the canonical signal, respectively. We found that, when transiently transfected into Ishikawa cells, the TopFlash reporter activated in response to treatment with purified Wnt7a and exhibited dose dependency. As shown in Fig. 5B , Wnt7a protein induces a 2-and 3.5-fold increase in reporter activation in control and cells stably expressing Fzd5, respectively. We also calculated the EC 50 value to be between 60 and 65 ng/mL for both cell types. We then tested whether the addition of SFRP4 protein could inhibit Wnt7a-induced reporter activity. Using a concentration of Wnt7a protein just above the EC 50 (100 ng/mL), SFRP4 protein was concurrently added to Fzd5 cells with Wnt7a at increasing doses. As shown in Fig. 5C , SFRP4 elicits a dose-responsive reduction in Wnt7a-mediated reporter activation. No effect was observed when SFRP4 was added alone, indicating that SFRP4 is suppressing h-catenin/ canonical signaling induced by the purified Wnt7a protein.
SFRP4 Functionally Inhibits Wnt7a-Induced Proliferation in Endometrial Cancer Cells
To determine the functional effect of Wnt7a and SFRP4 in Ishikawa cells, we used a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay to assess cell proliferation. At 48 h, a statistically significant increase in proliferation was observed when Fzd5 was cotransfected with Wnt7a (P V 0.001). Additionally, we found that SFRP4 significantly inhibited cell growth induced by Wnt7a/Fzd5 (P V 0.001; Fig. 6A ). No relevant effects on Ishikawa cell proliferation were observed in the presence of Fzd10. This result indicates that proliferation induced by Wnt7a is thereby an effect of canonical signaling mediated by Fzd5 and not the Fzd10-mediated JNK pathway.
We then aimed to parallel this finding using purified Wnt7a and SFRP4 proteins in Ishikawa cells stably overexpressing Fzd5. A statistically significant increase in proliferation was observed when Fzd5-overexpressing cells were treated with 100 ng/mL Wnt7a (P V 0.05). More intriguingly, we found that SFRP4 significantly inhibited cell growth induced by Wnt7a in a dose-dependent manner and also inhibited proliferation in the absence of exogenous Wnt7a (Fig. 6B) .
We next assayed the ability of SFRP4 to suppress endometrial cancer cell growth. Ishikawa cells were selected as a model because they do not natively express SFRP4. Cells were transfected with a SFRP4 construct and individual SFRP4-expressing and SFRP4-Null (cells transfected with SFRP4 construct, but not SFRP4 expressing based on Western blot) stable clones were selected for colony growth assays. SFRP4 expression markedly decreased colony formation by an overall average of f65% (Fig. 6C) .
Discussion
Previous studies have established that Wnt7a is important in the development and differentiation of the female reproductive tract. Although Wnt7a has been recognized as a major ligand in the endometrium, no information is available about its cognate Fzd partners or underlying signaling mechanism in the adult. Wnt7a has been shown to activate both canonical and noncanonical pathways in other cellular environments (33) (34) (35) (36) . Therefore, it could be expected that Wnt7a has multiple functions in the endometrium. Wnt7a was shown to signal via Fzd5/Lrp6 in neuronal PC12 cells as measured by increased h-catenin stability and activation of a T-cell factor reporter construct (37) . In situ hybridization of mouse embryos showed that Fzd10 is expressed in the same regions as Wnt7a in the neural tube, limb buds, and Mullerian duct (38) . Coinjection of Wnt7a and Fzd10 synergistically induces Wnt target genes in Xenopus embryos (39) . We conducted a microarray analysis to compile a panel of all Wnt components in the Ishikawa cell line and found significant expression of seven different Fzds, including Fzd5. Quantitative RT-PCR studies revealed positive expression of both Fzd5 and Fzd10 in human endometrial tissue. 1 Interestingly, little has been published on the localization of Fzds in the endometrium. Our in situ hybridization experiments confirmed that Fzd5 expression was restricted to both stroma and epithelium, whereas Fzd10 was localized solely to the stroma. Based on this information, Fzd5 and Fzd10 were predicted to be likely candidates for binding Wnt7a.
Our work confirms that Fzd5 and Fzd10 function as Wnt7a receptors in the endometrium and shows that Wnt7a can signal Fzd5-overexpressing Ishikawa cells treated with purified Wnt7a and/or SFRP4 proteins. Proliferation was measured 48 h after seeding for transfected cells and 3 d after treatment with purified proteins. Absorbance was measured at 490 nm 2 h after addition of MTS reagent. Columns, mean of three separate experiments in triplicate; bars, SE. Statistical significance is based on ANOVA and Bonferroni post hoc for multiple comparisons. *, P V 0.05, compared with EV or untreated controls; ***, P V 0.001, compared with EV or untreated controls; #, P V 0.01, compared with Wnt7a-treated cells; ##, P V 0.001, compared with Wnt7a-treated cells. C. Colony formation assay of SFRP4-Null and SFRP4 Ishikawa stable cell lines after selection with G418 for 2 wk. Colonies were quantified by crystal violet extraction. Columns, mean of three individual experiments; bars, SD. * P V 0.001, for SFRP4 stable clones compared with each SFRP4-Null clone based on Student's t test analysis.
via the h-catenin/canonical or noncanonical JNK-mediated pathway depending on which Fzd receptor it binds to on the cell. Wnt7a interaction with Fzd5 resulted in stabilization of cytoplasmic h-catenin and subsequent activation of h-catenin/ canonical signaling in a concentration-dependent manner. The binding of Wnt7a to Fzd10 induced the noncanonical JNKmediated pathway and increased phosphorylation of c-Jun. Because Fzd10 is localized to the endometrial stroma and our studies were done in epithelial cells, it may be of interest to further test whether the Wnt7a-Fzd10 interaction induces JNK signaling in endometrial stromal cells. The potential for one Wnt ligand to activate two separate signaling pathways in a cell through different receptors has also been recently shown by Mikels and Nusse (40) . However, this has never been reported for two individual Fzd receptors. The purification of large quantities of soluble active Wnt protein is extremely difficult and the biochemical properties of all 19 individual Wnts are not completely understood. We provide evidence that treatment of cells with purified recombinant Wnt7a protein is able to directly stimulate canonical Wnt signaling in a dose-dependent manner and induce proliferation.
There are several secreted proteins that can also interact with Wnt, including members of the SFRP family. SFRPs compete with Fzds to bind Wnt ligands and, in turn, modulate Wnt action. However, we should also note that previous publications have provided evidence for the formation of nonfunctional complexes between SFRP and Fzds (41) . The specific SFRPs that inhibit Wnt7a-Fzd interactions to provide feedback regulation in the endometrium have not been identified. In the present study, we have found that SFRP4 is localized to the endometrial stroma and its expression is significantly downregulated in certain types of endometrial carcinoma (26, 28, 29) .
1 SFRP4 expression peaks with high levels of estrogen during the proliferative phase of the menstrual cycle and significantly declines during the progesterone-dominated secretory phase (26, 42) . In contrast, epithelial expression of Wnt7a is much lower throughout the estrogen-driven proliferative phase (6) . Thus, increased expression of SFRP4 in response to estrogenic stimuli may assist in the estrogendependent down-regulation of Wnt7a through the binding of excess Wnt7a. We have discovered that SFRP4 can directly bind Wnt7a, and not the CRD of Fzd5, to prevent Wnt7a signaling in both an autocrine and paracrine fashion. We also found that purified SFRP4 inhibits Wnt7a-mediated proliferation and stable overexpression of SFRP4 functions to suppress endometrial cancer cell growth in vitro.
The intimate collaboration between endometrial stromal and epithelial cells is essential for normal adult function as well as for mediating the hormone-driven remodeling that accompanies the menstrual cycle (3, 4) . Given that Wnts are generally localized to different cell types and regulated by both estrogen and progesterone, it is presumed that they are key participants in this stromal-epithelial molecular dialogue. Wnt7a signaling mediated through its cognate Fzd5 and Fzd10 receptors may provide a molecular dialogue between epithelial and stromal cells, which can be modulated by SFRP4. We believe that disruption of this intercellular communication, through loss of SFRP4 expression, leads to excessive Wnt signaling, overactive h-catenin, and increased proliferation that may ultimately contribute to the onset of endometrial cancer. Based on our current findings, we believe that under normal circumstances SFRP4 can function as a suppressor of cell growth and may prove to hold therapeutic potential for endometrial carcinoma.
Materials and Methods
Cloning of Rat Wnt7a, Fzd5, Fzd10, and SFRP4
Rat uterine total RNA was isolated with Tri-Reagent (Molecular Research Center) and further purified using phenol chloroform extraction and isopropanol precipitation. RNA was washed with ethanol and resuspended in RNase-free diethyl pyrocarbonate water. Oligonucleotide primers were designed to flank the entire coding regions of rat Wnt7a, Fzd5, Fzd10, and SFRP4 for RT-PCR and subsequent ligation of recombinant cDNA into a pcDNA3.1 directional V5/6xHis TOPO vector (Invitrogen). Primer sequences for Wnt7a, Fzd5, and SFRP4 (Table 2) were designed against rat sequences in Genbank and modified to incorporate a COOH-terminal V5/6xHis-tag. Fzd10 was cloned by alignment of human Fzd10 Genbank sequence with the homologous region of the rat genome. Fzd10 cloning primers were designed to include the stop codon (Table 2) . Sitedirected mutagenesis was carried out using the cloned Fzd10 pcDNA3.1 construct and primers shown in Table 2 to convert the stop codon to a serine and reincorporate the COOH-terminal V5/6xHis-tag of pcDNA3.1. 
Microarray Analysis Using BeadChip Arrays
Microarray experiments were done on four Ishikawa biological replicates. RNA was isolated as described above and microarray analysis was done using HumanRef-8 BeadChip arrays (24,000 gene sequences/array) from Illumina. Briefly, RNA was amplified and cDNA was synthesized via reverse transcription. The cDNA was converted to cRNA containing biotinylated UTPs and incubated with avidin-labeled Cy3 dye. Each sample was then hybridized to a separate array on the BeadChip and incubated at 58jC overnight. Next day, bead chips were washed and scanned. BeadStudio 3 software (Illumina) was used for microarray data analysis.
In situ Hybridization of Endometrial Tissue
Twenty-one-day-old female Sprague-Dawley rats were purchased from Harlan and housed in accredited facilities at the University of Texas Houston Medical School. All federal guidelines and institutional policies about their treatment were followed. Animals were ovariectomized via a dorsal approach and uterine tissue was removed 5 d later. Tissue was formalin fixed and then cut into 10-Am paraffinembedded sections by the University of Texas Houston Histology Department. Digoxigenin-labeled mRNA sense and antisense probes targeting the 5 ¶ end of rat Wnt7a, Fzd5, Fzd10, and SFRP4 transcripts were generated using primers listed in Table 2 and in vitro transcription using the digoxigenin RNA labeling kit (Roche). In situ hybridization analysis was done using the methodology previously described (43) . Images were gathered by means of brightfield microscopy at Â100 magnification.
Cell Culture and Transfection
Ishikawa cells were grown in RPMI 1640 with glutamine, without phenol red (Invitrogen-Life Technologies), and supplemented with 10% fetal bovine serum, 0.01 mol/L HEPES, and penicillin/streptomycin. Cells were split 2 d before transient transfection and grown to 60% to 70% confluency. Transient transfections of Ishikawa cells (unless otherwise indicated) were conducted in 60-mm culture plates using FuGene 6 (Roche) according to the manufacturer's guidelines. All constructs were transfected at 1 Ag/dish unless otherwise specified.
To generate cell lines stably expressing Wnt7a-V5/His, SFRP4-V5/His, or the Fzd5-V5/His receptor, cells were plated out in 1:40 dilution 24 h after transfection and cultured under neomycin selection (600 Ag/mL G418) for 10 to 14 d. At least 12 clones expanded from single cells were screened for expression via RT-PCR and Western blot analysis.
Purification of Recombinant Wnt7a and SFRP4 6xHis-Tagged Proteins
6xHis-tagged proteins were purified from stable cells expressing Wnt7a-V5/His or SFRP4-V5/His by loading cleared lysate into Ni-NTA spin columns (Qiagen) and following protocol for mammalian cells under native conditions. Eluted samples were run through a second column and then dialyzed against PBS (pH 7.4) with addition of 1.0% CHAPS. Protein expression and purity were verified via Western blot analysis and Coomassie staining, respectively. Quantification was done using a 6xHis-tag -based ELISA protocol.
TopFlash and Phospho-c-Jun Luciferase Assays
The TopFlash and FopFlash firefly luciferase reporter constructs were transfected at 0.5 Ag/plate along with 0.1 Ag/ plate of the Renilla (pRL-TK) reporter to permit normalization of transfection efficiencies. Cells were harvested 24 h following transfection in 1Â passive lysis buffer (Promega Corp.). For coculture experiments, target cells were transfected in 60-mm plates and then reseeded into 12-well plates 24 h after transfection. Cells were allowed to recover for 6 h and then EV pcDNA3.0 or SFRP4-transfected effector cells from nearconfluent 60-mm plates were seeded onto the target cells to a final ratio of 2:1. Cells were harvested 24 h after seeding of effector cells. Wnt7a protein dose-response experiments were done in a similar manner. In place of effector cell coculture, cells were treated with purified recombinant Wnt7a and SFRP4 proteins as described in the text. For analysis of c-Jun activity, cells were transfected in six-well plates with 1 Ag/ well of pFR-Luc reporter construct and 0.05 Ag/well pFA2-cJun from the PathDetect c-Jun Trans-Reporting System (Stratagene), and 0.05 Ag/well of the Renilla (pRL-TK) reporter to permit normalization. All other expression constructs were transfected at 0.5 Ag/well. Luciferase activity was measured by a Monolight 2010 luminometer (Analytical Luminescence Laboratory) using the Dual-Luciferase Reporter Assay (Promega) as indicated by the manufacturer. Each experiment was repeated at least thrice in duplicate to ensure reproducibility.
Coimmunoprecipitation
For the Wnt7a-Fzd coimmunoprecipitation experiment, Ishikawa cells were harvested with radioimmunoprecipitation assay buffer [150 mmol/L NaCl, 1% Triton X-100, 1.0% deoxycholate, 0.1% SDS, 50 mmol/L Tris (pH 7.5), 5 mmol/L EDTA, 0.5 mmol/L phenylmethylsulfonyl fluoride] 24 h following transfection. Cell extracts were immunoprecipitated with goat anti-Wnt7a or goat anti-Fzd5 (Santa Cruz Biotechnology) using Protein A/G Plus-Agarose (Santa Cruz Biotechnology).
To detect interactions between Wnt7a and SFRP4, Ishikawa cells were treated with 2 mmol/L DTSSP crosslinker (Pierce) 24 h after transfection for 30 min to capture protein-protein interactions at the extracellular membrane. The cross-linking reaction was terminated by addition of 10 mmol/L Tris (pH 7.5) and cell lysis was done in Triton X-100 buffer (20 mmol/L HEPES, 1.0% Triton X-100, 250 mmol/L NaCl, 10% glycerol, 2 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 2.5 Ag/mL aprotinin, 2.5 Ag/mL leupeptin, 100 Amol/L sodium orthovanadate, 50 mmol/L sodium fluoride). Coimmunoprecipitation was conducted using either goat anti-Wnt7a or goat anti-SFRP4 (Santa Cruz Biotechnology). For experiments using purified proteins, 500 ng/mL Wnt7a and/or SFRP4 were immunoprecipitated in Triton X-100 buffer with either 500 ng/mL Fzd5CRD-Fc IgG (R&D Systems), Fc IgG (Bethyl Laboratories), or 1 Ag goat anti-Wnt7a.
Western Blot Analysis
Proteins isolated from coimmunoprecipitation experiments were electrophoresed on SDS-polyacrylamide gels and Western blot analysis was done using mouse anti-V5 (Invitrogen) or rabbit anti-human IgG (Santa Cruz Biotechnology). Immunoreactive proteins were visualized using secondary antibodies and the enhanced chemiluminescence Western blotting system (Amersham Biosciences).
To assess cytoplasmic h-catenin accumulation, transfected Ishikawa cells were lysed by hypotonic lysis as previously described (40) . Western blot was done with mouse anti-hcatenin (Santa Cruz Biotechnology) and mouse anti-h-actin (Chemicon International) for loading control normalization. Quantitation was done using GeneTools software (Syngene). To determine c-Jun phosphorylation, Western blot was done on total cell lysate using mouse anti-phospho-c-Jun and rabbit antic-Jun antibody (Santa Cruz Biotechnology). Protein expression of all transfected constructs was confirmed by Western blot analysis using mouse anti-V5.
Cell Proliferation Assay
Ishikawa cells were transfected with the Wnt component constructs as indicated in 60-mm plates. Transfectants were reseeded at 5 Â 10 3 cells per well in a 96-well culture plate 24 h after transfection. Cells stably overexpressing Fzd5 were seeded at 2.5 Â 10 3 per well in a 96-well culture plate. Cells were allowed to recover for 6 to 8 h and treated with 100 ng/mL Wnt7a and purified SFRP4 protein as indicated. The number of viable cells was evaluated 48 h after reseeding of transfected cells and 3 d after treatment with purified proteins by incubating for 2 h with the CellTiter 96 Aqueous NonRadioactive Cell Proliferation MTS Assay Reagent (Promega). Plates were read with a plate reader at a wavelength of 490 nm.
Colony Formation Assay
Ishikawa stable SFRP4 and SFRP4-Null cell lines were plated at 1,000 per well in six-well plate and grown with selection in G418 (600 Ag/mL) for 2 wk. Cells were stained with crystal violet, which was extracted with 1% SDS and quantificated at an absorbance of 590 nm.
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